Clinical trial
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of…
NCT00494442 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00494442 |
|---|---|
| Title | Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer |
| Official title | A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Ovarian Cancer |
| Acronym | ICEBERG 2 |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | KuDOS Pharmaceuticals Limited Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasm |
| Intervention type | Drug |
| Interventions | KU-0059436 (AZD2281)(PARP inhibitor) |
| Enrollment | 58 |
| Start date | Jun 11, 2007 |
| Primary completion | Mar 17, 2009 |
| Completion | Jul 20, 2017 |
| First posted | Jun 29, 2007 |
| Last update posted | Aug 1, 2018 |
| Countries | Australia, Germany, Spain, Sweden, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: